.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AB02_Treosulfan.Treosulfan .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AB02_Treosulfan.Treosulfan| name: | Treosulfan |
| ATC code: | L01AB02 | route: | intravenous |
| n-compartments | 2 |
Treosulfan is an alkylating agent used in conditioning regimens prior to hematopoietic stem cell transplantation (HSCT), mainly for treatment of hematological malignancies and some non-malignant diseases. It is currently approved and in clinical use in several countries for both adults and children as a part of preparative regimens for transplantation.
Pharmacokinetic parameters reported in adult patients undergoing allogeneic stem cell transplantation receiving intravenous treosulfan. Mean values from population PK analyses.
Rosser, SPA, et al., & Nath, CE (2023). Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations. British journal of clinical pharmacology 89(4) 1413–1424. DOI:10.1111/bcp.15599 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36369677
Danielak, D, et al., & Główka, F (2018). Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation. European journal of clinical pharmacology 74(1) 79–89. DOI:10.1007/s00228-017-2344-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/28975382
Li, X, et al., & Sykora, KW (2023). Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation. Drug metabolism and pharmacokinetics 52 100515–None. DOI:10.1016/j.dmpk.2023.100515 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37481830